X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26469) 26469
Book Review (13068) 13068
Publication (2921) 2921
Dissertation (1322) 1322
Book / eBook (618) 618
Book Chapter (444) 444
Conference Proceeding (102) 102
Newspaper Article (56) 56
Magazine Article (11) 11
Reference (7) 7
Data Set (4) 4
Paper (3) 3
Trade Publication Article (2) 2
Web Resource (2) 2
Government Document (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22953) 22953
humans (19616) 19616
animals (11290) 11290
biochemistry & molecular biology (8542) 8542
cancer (6609) 6609
oncology (5927) 5927
molecular targeted therapy (5101) 5101
female (4519) 4519
male (3991) 3991
molecular biology (3958) 3958
mice (3899) 3899
cell biology (3849) 3849
pharmacology & pharmacy (3744) 3744
research (3740) 3740
health aspects (3585) 3585
care and treatment (3462) 3462
analysis (2954) 2954
proteins (2784) 2784
medicine, research & experimental (2589) 2589
antineoplastic agents - therapeutic use (2567) 2567
article (2536) 2536
chemotherapy (2528) 2528
apoptosis (2470) 2470
gene expression (2453) 2453
review (2440) 2440
medicine (2424) 2424
tumors (2198) 2198
biology (2177) 2177
expression (2120) 2120
genetic aspects (2091) 2091
treatment outcome (2063) 2063
molecular medicine (1961) 1961
cell line, tumor (1951) 1951
signal transduction (1930) 1930
genetics & heredity (1894) 1894
mutation (1845) 1845
therapy (1838) 1838
physiological aspects (1793) 1793
middle aged (1781) 1781
genetics (1761) 1761
antineoplastic agents - pharmacology (1721) 1721
pharmacology (1719) 1719
in-vivo (1709) 1709
immunology (1686) 1686
neoplasms - drug therapy (1658) 1658
biotechnology & applied microbiology (1655) 1655
drug therapy (1642) 1642
research article (1605) 1605
inflammation (1592) 1592
metastasis (1570) 1570
adult (1560) 1560
aged (1520) 1520
signal transduction - drug effects (1482) 1482
development and progression (1477) 1477
immunotherapy (1426) 1426
in-vitro (1425) 1425
kinases (1425) 1425
risk factors (1414) 1414
cells (1413) 1413
drugs (1411) 1411
biomedicine (1396) 1396
molecular targeted therapy - methods (1383) 1383
prognosis (1375) 1375
medical research (1365) 1365
multidisciplinary sciences (1353) 1353
clinical trials (1351) 1351
science (1343) 1343
hematology (1331) 1331
chemistry, multidisciplinary (1328) 1328
clinical trials as topic (1313) 1313
cancer therapies (1299) 1299
drug discovery (1277) 1277
oxidative stress (1271) 1271
disease models, animal (1261) 1261
medicine & public health (1223) 1223
life sciences (1218) 1218
breast cancer (1213) 1213
drug design (1203) 1203
biochemistry (1192) 1192
antineoplastic agents - adverse effects (1167) 1167
cancer research (1165) 1165
rats (1156) 1156
rodents (1156) 1156
studies (1152) 1152
biophysics (1131) 1131
stem cells (1103) 1103
drug delivery systems (1093) 1093
breast-cancer (1080) 1080
patients (1061) 1061
chemistry (1058) 1058
nanoparticles (1048) 1048
genes (1042) 1042
usage (1036) 1036
neurosciences (1035) 1035
biomarkers (1031) 1031
gene therapy (1014) 1014
activation (1008) 1008
gene-expression (981) 981
toxicity (980) 980
inhibition (974) 974
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (406) 406
UofT at Mississauga - Stacks (61) 61
Collection Dvlpm't (Acquisitions) - Vendor file (59) 59
Collection Dvlpm't (Acquisitions) - Closed Orders (58) 58
Online Resources - Online (48) 48
UofT at Scarborough - Stacks (47) 47
Engineering & Comp. Sci. - Stacks (21) 21
UTL at Downsview - May be requested (15) 15
Earth Sciences (Noranda) - Stacks (9) 9
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (7) 7
Chemistry (A D Allen) - Stacks (5) 5
Gerstein Science - Reference (5) 5
Robarts - Stacks (5) 5
St. Michael's Hospital - Stacks (5) 5
Gerstein Science - Circulation Desk (4) 4
Collection Dvlpm't (Acquisitions) - Cancelled Order (3) 3
Media Commons - Microtexts (3) 3
Scarborough Hospital - Birchmount (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Trinity College (John W Graham) - Stacks (3) 3
UofT at Mississauga - Reference (3) 3
Gerstein Science - Course Reserves (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Mt Sinai Hospital - Pathology (2) 2
Providence Healthcare - Reference (2) 2
Providence Healthcare - Reserve desk (2) 2
Scarborough Hospital - General (2) 2
Credit Valley Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Earth Sciences (Noranda) - Missing (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Closed Orders (1) 1
Gerstein Science - May be requested (1) 1
Gerstein Science - Reference Desk (1) 1
Gerstein Science - Searching (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
OISE - Curriculum Resources (1) 1
Physics - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Toronto East General Hospital - Stacks (1) 1
UofT at Mississauga - Missing (1) 1
UofT at Mississauga - Not Returned (1) 1
UofT at Scarborough - May be requested (1) 1
Victoria University E.J. Pratt - Reference (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28485) 28485
Japanese (129) 129
Spanish (85) 85
German (64) 64
French (50) 50
Czech (11) 11
Chinese (8) 8
Russian (8) 8
Hungarian (6) 6
Polish (4) 4
Swedish (2) 2
Arabic (1) 1
Dutch (1) 1
Hebrew (1) 1
Italian (1) 1
Korean (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1324 - 1334
Journal Article
Circulation, ISSN 0009-7322, 11/2015, Volume 132, Issue 18, pp. 1693 - 1700
BACKGROUND—The goal of this work was to assess the safety and efficacy of biologics (ie, tumor necrosis factor-α antagonists and tocilizumab) in patients with... 
Treatment outcome | Biological therapy | Vasculitis | Takayasu arteritis | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | vasculitis | COMPETING RISK | biological therapy | REFERRAL CENTER | treatment outcome | DISEASE-ACTIVITY | TOCILIZUMAB | FACTOR THERAPY | TERM-FOLLOW-UP | MALIGNANCIES | PERIPHERAL VASCULAR DISEASE | NECROSIS-FACTOR INHIBITORS | TNF-ALPHA | Blood Sedimentation | Angiography | Humans | Middle Aged | Drug Evaluation | Takayasu Arteritis - diagnostic imaging | Male | Infliximab - therapeutic use | Adalimumab - adverse effects | Young Adult | Infliximab - adverse effects | Takayasu Arteritis - blood | Antirheumatic Agents - adverse effects | Adult | Female | Retrospective Studies | C-Reactive Protein - analysis | Drug Therapy, Combination | Drug Resistance | Antirheumatic Agents - therapeutic use | Antibodies, Monoclonal, Humanized - adverse effects | Takayasu Arteritis - drug therapy | Etanercept - adverse effects | Molecular Targeted Therapy - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Proportional Hazards Models | Treatment Outcome | Disease-Free Survival | Adalimumab - therapeutic use | Prednisone - therapeutic use | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Care and treatment | Usage | Diagnosis | Takayasu's arteritis | Tumor necrosis factor inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 293 - 300
Journal Article
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 5/2013, Volume 40, Issue 5, pp. 800 - 816
Journal Article
The Lancet Oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 310 - 322
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 3, pp. 411 - 419
Toxicities associated with vascular endothelial growth factor–targeted therapies can often compromise clinical benefit in patients with metastatic renal cell... 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | toxicity | renal cell carcinoma | risk factors | treatment discontinuation | model | VEGF‐targeted therapies | VEGF-targeted therapies | SAFETY | OLDER-ADULTS | PHASE-III | SORAFENIB | CANCER | INTERFERON-ALPHA | ANGIOGENESIS INHIBITOR THERAPIES | ONCOLOGY | TREATMENT PATTERNS | SUNITINIB | CLINICAL-PRACTICE | Predictive Value of Tests | Humans | Middle Aged | Male | Fatigue - chemically induced | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Indoles - administration & dosage | Kidney Neoplasms - blood | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Bevacizumab - administration & dosage | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Niacinamide - adverse effects | Mucositis - chemically induced | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Indazoles - adverse effects | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Bevacizumab - adverse effects | Imidazoles - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Retrospective Studies | Vascular Endothelial Growth Factor A - drug effects | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Databases, Factual | Molecular Targeted Therapy - adverse effects | Carcinoma, Renal Cell - blood | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Models, Statistical | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Care and treatment | Dosage and administration | Carcinoma, Renal cell | Diagnosis | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2017, Volume 84, pp. 44 - 54
Targeted therapy (TT) and immunotherapies (ITs) have dramatically improved survival in metastatic melanoma (MM). However, their efficacy on brain metastasis... 
Targeted therapies | Check-point inhibitors | Gamma-Knife radiosurgery | Brain metastasis | Melanoma | OPEN-LABEL | RADIATION | ANTI-PD-1 THERAPY | STEREOTACTIC RADIOSURGERY | REAL-WORLD | ONCOLOGY | INHIBITORS | IPILIMUMAB | PHASE-2 TRIAL | CLINICAL-OUTCOMES | VEMURAFENIB | Multivariate Analysis | Immunotherapy - methods | Humans | Middle Aged | Melanoma - enzymology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Radiosurgery - adverse effects | Brain Neoplasms - secondary | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Female | Retrospective Studies | Brain Neoplasms - mortality | Chemotherapy, Adjuvant | MAP Kinase Kinase Kinases - antagonists & inhibitors | Radiosurgery - methods | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins B-raf - metabolism | Skin Neoplasms - pathology | Antibodies - therapeutic use | Brain Neoplasms - enzymology | Molecular Targeted Therapy - adverse effects | Skin Neoplasms - therapy | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Antibodies - adverse effects | MAP Kinase Kinase Kinases - metabolism | Melanoma - secondary | Immunotherapy - adverse effects | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Brain Neoplasms - therapy | Mutation | Programmed Cell Death 1 Receptor - immunology | Melanoma - therapy | Melanoma - mortality | Care and treatment | Metastasis | Patient outcomes | Surgery | Immunotherapy | Radiosurgery | Analysis | Brain | Therapy | Elk | MEK inhibitors | Breast cancer | Multivariate analysis | Patients | Survival | Metastases | Inhibitors | Radiology | Movement disorders | Index Medicus
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2012, Volume 39, Issue 4, pp. 388 - 401
Abstract Background To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and... 
Hematology, Oncology and Palliative Medicine | Side effects | Adverse events | Targeted therapy | Renal cell carcinoma | SUNITINIB TREATMENT | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | BLOOD-PRESSURE | PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | INTERFERON-ALPHA | ONCOLOGY | NASAL-SEPTUM PERFORATION | QUALITY-OF-LIFE | JAPANESE PATIENTS | FOOT SKIN REACTION | Niacinamide - analogs & derivatives | Humans | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Protein Kinase Inhibitors - adverse effects | Bevacizumab | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Molecular Targeted Therapy - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Imidazoles - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects